A Review of Antineoplastic Agents Associated Nephrotoxicity, an Understood Complication
Journal of Pediatric Nephrology,
Vol. 8 No. 1 (2020),
19 May 2020
,
Page 1-8
https://doi.org/10.22037/jpn.v8i1.30318
Abstract
In the recent decades, the survival of children with cancer has improved dramatically. This improvement is due to use of different chemotherapeutic agents, but the majority of these drugs have kidney toxicities. Deterioration of renal function due to antineoplastic agents is the main limiting factor for administration of these drugs. Chemotherapeutic agents could result in an acute or chronic injury in glomeruli or tubules. Overall childhood cancer survivors have a nine-fold higher risk of developing kidney function impairment when compared with their sibling. In this review, the nephrotoxicity due to some chemotherapeutic drugs such as platinum agents, ifosfamide, methotrexate(MTX), doxorubicin, gemcitabine and imatinib have been discussed.
Keywords: Antineoplastic; Cancer; Chemotherapy; Nephrotoxicity.
How to Cite
References
Jones DP, Spunt SL, Green D, Springate JE. Renal late effects in patients treated for cancer in childhood: a report from the Children's Oncology Group. Pediatric blood & cancer. 2008 Dec;51(6):724-31.
Fujieda M, Matsunaga A, Hayashi A, Tauchi H, Chayama K, Sekine T. Children’s toxicology from bench to bed-Drug-induced Renal Injury (2): Nephrotoxiciy induced by cisplatin and ifosfamide in children. The Journal of toxicological sciences. 2009 Jul 1;34(Special):SP251-7.
Ganguli A, Sawinski D, Berns JS. Kidney diseases associated with haematological cancers. Nature Reviews Nephrology. 2015 Aug;11(8):478.
Lameire N. Nephrotoxicity of recent anti-cancer agents. Clinical kidney journal. 2014 Feb 1;7(1):11-22.
Shirali AC, Perazella MA. Tubulointerstitial injury associated with chemotherapeutic agents. Advances in chronic kidney disease. 2014 Jan 1;21(1):56-63.
Perazella MA, Moeckel GW. Nephrotoxicity from chemotherapeutic agents: clinical manifestations, pathobiology, and prevention/therapy. In Seminars in nephrology 2010 Nov 1 (Vol. 30, No. 6, pp. 570-581). WB Saunders.
Skinner R. Late renal toxicity of treatment for childhood malignancy: risk factors, long-term outcomes, and surveillance. Pediatric Nephrology. 2018 Feb 1;33(2):215-25.
Perazella MA. Onco-nephrology: renal toxicities of chemotherapeutic agents. Clinical Journal of the American Society of Nephrology. 2012 Oct 1;7(10):1713-21.
Sahni V, Choudhury D, Ahmed Z. Chemotherapy-associated renal dysfunction. Nature Reviews Nephrology. 2009 Aug;5(8):450.
Safirstein RL. Renal diseases induced by antineoplastic agents. In: Schrier RW (ed.). Diseases of the Kidney and Urinary Tract. Philadelphia: Wolters, Kluwer, Lippincott, Williams and Wilkins, 2007, pp. 1068–81.
Janus N, Launay-Vacher V, Byloos E, Machiels JP, Duck L, Kerger J, Wynendaele W, Canon JL, Lybaert W, Nortier J, Deray G. Cancer and renal insufficiency results of the BIRMA study. British journal of cancer. 2010 Dec;103(12):1815-21.
Al-Tonbary YA, Hammad AM, Zaghloul HM, El-Sayed HE, Abu-Hashem E. Pretreatment cystatin C in children with malignancy: can it predict chemotherapy-induced glomerular filtration rate reduction during the induction phase? Journal of pediatric hematology/oncology. 2004 Jun 1;26(6):336-41.
Bárdi E, Bobok I, Oláh AV, Oláh É, Kappelmayer J, Kiss C. Cystatin C is a suitable marker of glomerular function in children with cancer. Pediatric Nephrology. 2004 Oct 1;19(10):1145-7.
Pedrosa DC, de Oliveira Neves FM, Meneses GC, Wirtzbiki GP, da Costa Moraes CA, Martins AM, Libório AB. Urinary KIM-1 in children undergoing nephrotoxic antineoplastic treatment: a prospective cohort study. Pediatric Nephrology. 2015 Dec 1;30(12):2207-13.
Yao X, Panichpisal K, Kurtzman N, Nugent K. Cisplatin nephrotoxicity: a review. The American journal of the medical sciences. 2007 Aug 1;334(2):115-24.
Manohar S, Leung N. Cisplatin nephrotoxicity: a review of the literature. Journal of nephrology. 2018 Feb 1;31(1):15-25.
Sánchez-González PD, López-Hernández FJ, López-Novoa JM, Morales AI. An integrative view of the pathophysiological events leading to cisplatin nephrotoxicity. Critical reviews in toxicology. 2011 Nov 1;41(10):803-21.
dos Santos NA, Rodrigues MA, Martins NM, Dos Santos AC. Cisplatin-induced nephrotoxicity and targets of nephroprotection: an update. Archives of toxicology. 2012 Aug 1;86(8):1233-50.
Peres LA, da Cunha Jr AD. Acute nephrotoxicity of cisplatin: molecular mechanisms. J Bras Nefrol. 2013 Oct;35(4):332-40.
Pabla N, Dong Z. Cisplatin nephrotoxicity: mechanisms and renoprotective strategies. Kidney international. 2008 May 1;73(9):994-1007.
Oh GS, Kim HJ, Shen A, Lee SB, Khadka D, Pandit A, So HS. Cisplatin-induced kidney dysfunction and perspectives on improving treatment strategies. Electrolytes & Blood Pressure. 2014 Dec 1;12(2):55-65.
Karasawa T, Steyger PS. An integrated view of cisplatin-induced nephrotoxicity and ototoxicity. Toxicology letters. 2015 Sep 17;237(3):219-27.
Barabas K, Milner R, Lurie D, Adin C. Cisplatin: a review of toxicities and therapeutic applications. Veterinary and comparative oncology. 2008 Mar;6(1):1-8.
Taguchi T, Nazneen A, Abid MR, Razzaque MS. Cisplatin-associated nephrotoxicity and pathological events. InCellular Stress Responses in Renal Diseases 2005 (Vol. 148, pp. 107-121). Karger Publishers.
Skinner, R., Parry, A., Price, L., Cole, M., Craft, A.W. and Pearson, A.D., 2009. Persistent nephrotoxicity during 10-year follow-up after cisplatin or carboplatin treatment in childhood: relevance of age and dose as risk factors. European journal of cancer, 45(18), pp.3213-3219.
Hanigan MH, Devarajan P. Cisplatin nephrotoxicity: molecular mechanisms. Cancer therapy. 2003;1:47.
Miller RP, Tadagavadi RK, Ramesh G, Reeves WB. Mechanisms of cisplatin nephrotoxicity. Toxins. 2010 Nov;2(11):2490-518.
Kidera Y, Kawakami H, Sakiyama T, Okamoto K, Tanaka K, Takeda M, Kaneda H, Nishina SI, Tsurutani J, Fujiwara K, Nomura M. Risk factors for cisplatin-induced nephrotoxicity and potential of magnesium supplementation for renal protection. PloS one. 2014;9(7).
Hayati F, Hossainzadeh M, Shayanpour S, Abedi-Gheshlaghi Z, Mousavi SS. Prevention of cisplatin nephrotoxicity. Journal of nephropharmacology. 2016;5(1):57.
Arany I, Safirstein RL. Cisplatin nephrotoxicity. InSeminars in nephrology 2003 Sep 1 (Vol. 23, No. 5, pp. 460-464). WB Saunders.
Ali BH, Al Moundhri MS. Agents ameliorating or augmenting the nephrotoxicity of cisplatin and other platinum compounds: a review of some recent research. Food and chemical toxicology. 2006 Aug 1;44(8):1173-83.
de Jongh FE, van Veen RN, Veltman SJ, de Wit R, van der Burg ME, van den Bent MJ, et al. Weekly high-dose cisplatin is a feasible treatment option: analysis on prognostic factors for toxicity in 400 patients. Br J Cancer. 2003;88:1199-206.
Santoso JT, Lucci JA 3rd, Coleman RL, Schafer I, Hannigan EV. Saline, mannitol, and furosemide hydration in acute cisplatin nephrotoxicity: a randomized trial. Cancer Chemother Pharmacol. 2003;52:13-8.
Hemati S, Arbab Jolfaie N, Rafienia M, Ghavamnasiri M. The effects of vitamin E and selenium on cisplatin-induced nephrotoxicity in cancer patients treated with cisplatin-based chemotherapy: a randomized, placebo-controlled study. J Res Med Sci. 2012;17:S49–58.
35-Sheu SS, Nauduri D, Anders MW. Targeting antioxidants to mitochondria: a new therapeutic direction. Biochim Biophys Acta. 2006;1762:256-65.
Hensley ML, Hagerty KL, Kewalramani T, Green DM, Meropol NJ, Wasserman TH, Cohen GI, Emami B, Gradishar WJ, Mitchell RB, Thigpen JT. American Society of Clinical Oncology 2008 clinical practice guideline update: use of chemotherapy and radiation therapy protectants. Journal of clinical oncology. 2009 Jan 1;27(1):127-45.
Butani L, West DC, Taylor DS. End-stage renal disease after high-dose carboplatinum in preparation of autologous stem cell transplantation. Pediatr Transplant 2003;7:408–12.
de Jonge MJ, Verweij J. Renal toxicities of chemotherapy. In Seminars in oncology 2006 Feb 1 (Vol. 33, No. 1, pp. 68-73). WB Saunders.
Stöhr W, Paulides M, Bielack S, Jürgens H, Koscielniak E, Rossi R, Langer T, Beck JD. Nephrotoxicity of cisplatin and carboplatin in sarcoma patients: a report from the late effects surveillance system. Pediatric blood & cancer. 2007 Feb;48(2):140-7.
Fukasawa H, Furuya R, Yasuda H, Yamamoto T, Hishida A, Kitagawa M. Anti-cancer agent-induced nephrotoxicity. Anti-Cancer Agents in Medicinal Chemistry (Formerly Current Medicinal Chemistry-Anti-Cancer Agents). 2014 Sep 1;14(7):921-7.
Gomes SM, Garcia AM, Francisco T, Teixeira G, Ribeiro MJ, Serrão AP. Fanconi syndrome after Ifosfamide exposure-case report. Portuguese Journal of Nephrology & Hypertension. 2019 Mar;33(1):61-7.
Berrak SG, Pearson M, Berberoğlu S, Ilhan IE, Jaffe N. High‐dose ifosfamide in relapsed pediatric osteosarcoma: Therapeutic effects and renal toxicity. Pediatric blood & cancer. 2005 Mar;44(3):215-9.
Kintzel PE. Anticancer drug—induced kidney disorders. Drug safety. 2001 Jan 1;24(1):19-38.
Lee BS, Lee JH, Kang HG, Hahn H, Lee JH, Shin HY, Ha IS, Cheong HI, Ahn HS, Choi Y. Ifosfamide nephrotoxicity in pediatric cancer patients. Pediatric Nephrology. 2001 Oct 1;16(10):796-9.
Widemann BC, Adamson PC. Understanding and managing methotrexate nephrotoxicity. The oncologist. 2006 Jun 1;11(6):694-703.
Flombaum CD, Liu D, Yan SQ, Chan A, Mathew S, Meyers PA, Glezerman IG, Muthukumar T. Management of Patients with Acute Methotrexate Nephrotoxicity with High‐Dose Leucovorin. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy. 2018 Jul;38(7):714-24.
Cavone JL, Yang D, Wang A. Glucarpidase intervention for delayed methotrexate clearance. Ann Pharmacother 2014;48 (7):897–907.
48-Widemann BC. Practical considerations for the administration of glucarpidase in high-dose methotrexate (HDMTX) induced renal dysfunction. Pediatr Blood Cancer 2015;62(9):1512–3.
Widemann BC, Balis FM, Kim A, Boron M, Jayaprakash N, Shalabi A, O'Brien M, Eby M, Cole DE, Murphy RF, Fox E. Glucarpidase, leucovorin, and thymidine for high-dose methotrexate-induced renal dysfunction: clinical and pharmacologic factors affecting outcome. Journal of clinical oncology. 2010 Sep 1;28(25):3979.
Widemann BC, Schwartz S, Jayaprakash N, Christensen R, Pui CH, Chauhan N, Daugherty C, King TR, Rush JE, Howard SC. Efficacy of Glucarpidase (Carboxypeptidase G 2) in Patients with Acute Kidney Injury After High‐Dose Methotrexate Therapy. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy. 2014 May;34(5):427-39.
Iqbal S, Armaghani A, Aiyer R, Kazory A. Methotrexate nephrotoxicity: Novel treatment, new approach. Journal of Oncology Pharmacy Practice. 2013 Dec;19(4):373-6.
Shahbazi F, Dashti-Khavidaki S, Khalili H, Lessan-Pezeshki M. Potential renoprotective effects of silymarin against nephrotoxic drugs: a review of literature. Journal of Pharmacy & Pharmaceutical Sciences. 2012 Jan 20;15(1):112-23.
Małyszko J, Kozłowska K, Kozłowski L, Małyszko J. Nephrotoxicity of anticancer treatment. Nephrology Dialysis Transplantation. 2017 Jun 1;32(6):924-36.
Delaney V, de Pertuz Y, Nixon D, Bourke E. Indomethacin in streptozocin-induced nephrogenic diabetes insipidus. American Journal of Kidney Diseases. 1987 Jan 1;9(1):79-83.
Rapkin L, Qayed M, Brill P, Martin M, Clark D, George BA, Olson TA, Wasilewski‐Masker K, Alazraki A, Katzenstein HM. Gemcitabine and docetaxel (GEMDOX) for the treatment of relapsed and refractory pediatric sarcomas. Pediatric blood & cancer. 2012 Nov;59(5):854-8.
Izzedine H, Isnard-Bagnis C, Launay-Vacher V, Mercadal L, Tostivint I, Rixe O, Brocheriou I, Bourry E, Karie S, Saeb S, Casimir N. Gemcitabine-induced thrombotic microangiopathy: a systematic review. Nephrology Dialysis Transplantation, 2006; 21(11):3038–3045
Gore EM, Jones BS, Marques MB. Is therapeutic plasma exchange indicated for patients with gemcitabine‐induced hemolytic uremic syndrome? Journal of Clinical Apheresis: The Official Journal of the American Society for Apheresis. 2009;24(5):209-14.
Bharthuar A, Egloff L, Becker J, George M, Lohr JW, Deeb G, Iyer RV. Rituximab-based therapy for gemcitabine-induced hemolytic uremic syndrome in a patient with metastatic pancreatic adenocarcinoma: a case report. Cancer chemotherapy and pharmacology. 2009 Jun 1;64(1):177.
Gourley BL, Mesa H, Gupta P. Rapid and complete resolution of chemotherapy-induced thrombotic thrombocytopenic purpura/hemolytic uremic syndrome (TTP/HUS) with rituximab. Cancer chemotherapy and pharmacology. 2010 Apr 1;65(5):1001-4.
Ayla S, Seckin I, Tanriverdi G, Cengiz M, Eser M, Soner BC, Oktem G. Doxorubicin induced nephrotoxicity: protective effect of nicotinamide. International journal of cell biology. 2011;2011.
Kitiyakara C, Atichartakarn V. Renal failure associated with a specific inhibitor of BCR‐ABL tyrosine kinase, STI 571. Nephrology Dialysis Transplantation. 2002 Apr 1;17(4):685-7.
Pou M, Saval N, Vera M, Saurina A, Solé M, Cervantes F, Botey A. Acute renal failure secondary to imatinib mesylate treatment in chronic myeloid leukemia. Leukemia & lymphoma. 2003 Jul 1;44(7):1239-41.
Foringer JR, Verani RR, Tjia VM, Finkel KW, Samuels JA, Guntupalli JS. Acute renal failure secondary to imatinib mesylate treatment in prostate cancer. Annals of Pharmacotherapy. 2005 Dec;39(12):2136-8.
Marcolino MS, Boersma E, Clementino NC, Macedo AV, Marx-Neto AD, Silva MH, van Gelder T, Akkerhuis KM, Ribeiro AL. Imatinib treatment duration is related to decreased estimated glomerular filtration rate in chronic myeloid leukemia patients. Annals of oncology. 2011 Sep 1;22(9):2073-9.
François H, Coppo P, Hayman JP, Fouqueray B, Mougenot B, Ronco P. Partial fanconi syndrome induced by imatinib therapy: a novel cause of urinary phosphate loss. American journal of kidney diseases. 2008 Feb 1;51(2):298-301.
Holstein SA, Stokes JB, Hohl RJ. Renal failure and recovery associated with second-generation Bcr-Abl kinase inhibitors in imatinib-resistant chronic myelogenous leukemia. Leukemia research. 2009 Feb 1;33(2):344-7.
- Abstract Viewed: 241 times
- PDF Downloaded: 175 times